Business Description
NeuroSense Therapeutics Ltd
ISIN : IL0011809592
Total Employee Number:
16Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.98 | |||||
Equity-to-Asset | -1.52 | |||||
Debt-to-Equity | -0.11 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22 | |||||
3-Year EPS without NRI Growth Rate | 21.6 | |||||
3-Year FCF Growth Rate | 23.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 34.28 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.16 | |||||
9-Day RSI | 48.91 | |||||
14-Day RSI | 47.83 | |||||
3-1 Month Momentum % | 13.23 | |||||
6-1 Month Momentum % | 8.99 | |||||
12-1 Month Momentum % | -55.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.31 | |||||
Quick Ratio | 0.31 | |||||
Cash Ratio | 0.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.3 | |||||
Shareholder Yield % | -16.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -6622.02 | |||||
ROA % | -458.01 | |||||
ROIC % | -4605.96 | |||||
3-Year ROIIC % | 127.95 | |||||
ROC (Joel Greenblatt) % | -6885.09 | |||||
ROCE % | -5773.44 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.47 | |||||
EV-to-Forward-EBIT | -1.31 | |||||
EV-to-EBITDA | -2.48 | |||||
EV-to-Forward-Revenue | 25.62 | |||||
EV-to-FCF | -3.57 | |||||
Earnings Yield (Greenblatt) % | -40.49 | |||||
FCF Yield % | -28.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRSN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeuroSense Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.44 | ||
| Beta | 4.5866 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 70.85 | ||
| 14-Day RSI | 47.83 | ||
| 14-Day ATR ($) | 0.068856 | ||
| 20-Day SMA ($) | 0.75966 | ||
| 12-1 Month Momentum % | -55.96 | ||
| 52-Week Range ($) | 0.63 - 2.19 | ||
| Shares Outstanding (Mil) | 36.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuroSense Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroSense Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 48 days | ||
| First quarter earnings results for 2026 | 2026-06-26 | 0.76 (-5.24%) | ||
| Annual report for 2025 | 2026-03-31 | 0.73 (+2.04%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 0.73 (+2.04%) | ||
| Third quarter earnings results for 2025 | 2025-12-18 | 0.83 (-2.13%) | ||
| NeuroSense Investor Webinar | 2025-12-08 08:30 | 1.17 (-3.31%) | ||
| NeuroSense CEO Alon Ben-Noon in a Special Live Podcast | 2025-08-04 14:00 | 1.08 (-38.29%) | ||
| First quarter earnings results for 2025 | 2025-06-24 | 2.13 (-8.58%) | ||
| Annual report for 2024 | 2025-04-07 | 0.99 (+15.12%) |
Show
Entries
NeuroSense Therapeutics Ltd Frequently Asked Questions
What is NeuroSense Therapeutics Ltd(NRSN)'s stock price today?
The current price of NRSN is $0.76. The 52 week high of NRSN is $2.19 and 52 week low is $0.63.
When is next earnings date of NeuroSense Therapeutics Ltd(NRSN)?
The next earnings date of NeuroSense Therapeutics Ltd(NRSN) is 2026-08-14 Est..
Does NeuroSense Therapeutics Ltd(NRSN) pay dividends? If so, how much?
NeuroSense Therapeutics Ltd(NRSN) does not pay dividend.
Guru Commentaries on NAS:NRSN
No articles.
Press Release
Articles on NeuroSense Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers